Nearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that ...

The biotech's Phase 2a study of bempikibart showed a 35.3% mean reduction in hair loss scores, with the company planning a ...

The trial enrolled 33 patients with severe or very severe forms of AA, most with baseline SALT scores between 50 and 100.

Q32 Bio (NASDAQ:QTTB) reported positive 36-week top-line results from Part B of its SIGNAL-AA Phase 2a clinical trial ...

Phase 2 Data Boosts Investor Confidence Q32 Bio Inc. (NASDAQ:QTTB) shares surged 60% on Monday after the biotechnology ...

Autologous fat grafting offers hope for patients with alopecia, especially those with scarring, by reducing inflammation and stimulating hair growth. Patients with alopecia are either diagnosed with ...

A Phase 2a clinical study of Q32 Bio's investigational antibody treatment, bempikibart, in patients with severe or very ...

Sponsored by Pfizer. Dr. Soung was compensated for her time. If you’re among the nearly 7 million people in the United States living with alopecia areata, you know that treating hair loss can be an ...

Please provide your email address to receive an email when new articles are posted on . A literature review found cryotherapy yielded a lower relapse rate in alopecia areata vs. other treatments.

Add Popular Science (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results.

Alopecia areata is an autoimmune disorder that usually results in unpredictable, patchy hair loss. Approximately 7 million people in the U.S. have alopecia areata, and it can affect anyone of any age ...